In the last few decades, the treatment regimen for Gastric Cancer (GC) remains unchanged with minimal scope of targeted therapy. Additionally, targeted therapy is generally effective in only a subset of patients and majority of the targeted therapies have failed as GC has been very poorly characterized from a molecular point of view. Recent classification systems proposed by The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) have identified molecular subtypes with distinct molecular alterations specific to each subtype.
In my study, I am trying to understand how alterations in the Receptor Tyrosine Kinase (RTK) genes and Cyclins lead to aggressiveness of GC with special attention to the tumor suppressor P53 and autophagy.
